Activity

The US FDA, Pending The Clinical Benefit Study, Has Conditionally Approved The First New Alzheimer’s Disease Drug, Since A Drug Was Last Approved In Almost 20 Years, In 2003. The Novel Experimental Drug, Known As Aducanumab Or Aduhelm, Is Intended For Patients With Earliest Stage Of Dementia, And To Slow Alzheimer’s Disease Progression.